Condition: Chronic Hepatitis B · Sponsor: Ausper Biopharma Co., Ltd.
A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.
This description comes directly from the study's public registry record.
Lu · 0571-86959519 · clinicaltrial@ausperbio.com
Always discuss trial participation with your own doctor first.
| AusperBio Investigational Site | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| AusperBio Investigational Site | Zhengzhou, Henan, China | Not Yet Recruiting |
| Huashan Hospital Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| AusperBio Investigational Site | Chengdu, Sichuan, China | Not Yet Recruiting |
| AusperBio Investigational Site | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07600788